NO20061085L - Kombinasjonsterapi for glykemisk kontroll - Google Patents

Kombinasjonsterapi for glykemisk kontroll

Info

Publication number
NO20061085L
NO20061085L NO20061085A NO20061085A NO20061085L NO 20061085 L NO20061085 L NO 20061085L NO 20061085 A NO20061085 A NO 20061085A NO 20061085 A NO20061085 A NO 20061085A NO 20061085 L NO20061085 L NO 20061085L
Authority
NO
Norway
Prior art keywords
combination therapy
glycemic control
diabetes mellitus
diabetes
niddm
Prior art date
Application number
NO20061085A
Other languages
English (en)
Norwegian (no)
Inventor
Hans-Ulrich Demuth
Matthias Hoffmarm
Konrad Glund
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of NO20061085L publication Critical patent/NO20061085L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20061085A 2003-09-02 2006-03-06 Kombinasjonsterapi for glykemisk kontroll NO20061085L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (fr) 2003-09-02 2004-09-02 Therapie combinee de regulation glycemique

Publications (1)

Publication Number Publication Date
NO20061085L true NO20061085L (no) 2006-05-31

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061085A NO20061085L (no) 2003-09-02 2006-03-06 Kombinasjonsterapi for glykemisk kontroll

Country Status (14)

Country Link
US (1) US20060287251A1 (fr)
EP (1) EP1663200A2 (fr)
JP (1) JP2007504213A (fr)
KR (1) KR20060119927A (fr)
CN (1) CN1845731A (fr)
AU (1) AU2004267955A1 (fr)
BR (1) BRPI0413204A (fr)
CA (1) CA2536432A1 (fr)
EA (1) EA200600356A1 (fr)
IL (1) IL173844A0 (fr)
MX (1) MXPA06002127A (fr)
NO (1) NO20061085L (fr)
WO (1) WO2005020983A2 (fr)
ZA (1) ZA200601770B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
WO2011117417A1 (fr) * 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues de glucagon
SG11201401175SA (en) * 2011-10-28 2014-09-26 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
ATE349435T1 (de) * 2002-02-28 2007-01-15 Prosidion Ltd Dpiv-inhibitoren auf glutaminbasis
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)

Also Published As

Publication number Publication date
WO2005020983A3 (fr) 2005-07-28
CN1845731A (zh) 2006-10-11
WO2005020983A2 (fr) 2005-03-10
AU2004267955A1 (en) 2005-03-10
US20060287251A1 (en) 2006-12-21
ZA200601770B (en) 2007-07-25
EP1663200A2 (fr) 2006-06-07
KR20060119927A (ko) 2006-11-24
IL173844A0 (en) 2006-07-05
BRPI0413204A (pt) 2006-10-03
JP2007504213A (ja) 2007-03-01
EA200600356A1 (ru) 2006-08-25
CA2536432A1 (fr) 2005-03-10
MXPA06002127A (es) 2006-05-31

Similar Documents

Publication Publication Date Title
MXPA05007485A (es) Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
CA2434682A1 (fr) Combinaisons d'activateur(s) du recepteur active par le proliferateur de peroxysome et d'inhibiteur(s) d'absorption des sterols, et traitements pour troubles vasculaires
PH12016501607B1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
MXPA05002930A (es) Composiciones para la inhibicion de la proteina cinasa c alfa para el tratamiento de diabetes mellitus y enfermedades cardiovasculares.
BR0206644A (pt) Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
UA102429C2 (ru) Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
IL186356A0 (en) Method of treating of preventing type-2 diabetes
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
WO2005034737A3 (fr) Diagnostic et traitement de troubles du reticulum endoplasmique
WO2004024066A3 (fr) Methode de traitement du diabete et d'etats associes
EA200600356A1 (ru) Комбинированная терапия для гликемического контроля
BR0103209A (pt) Uso de ácido fitânico para o tratamento de diabetes
DE602004018162D1 (de) hERG1-KANAL-ÖFFNER ZUR BEHANDLUNG VON HERZARRYTHMIEN
UA92450C2 (ru) 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
EP2096120A3 (fr) Utilisation de produits à protéines sécrétées pour empêcher et traiter les maladies pancréatiques et/ou l'obésité et/ou un syndrome métabolique
NO20033401L (no) Kjemiske forbindelser
WO2024163383A9 (fr) Traitement de l'amyotrophie spinale (sma) par modulation de mir34 et utilisation de mir34 en tant que biomarqueur prédictif de sma
WO2004001071A3 (fr) Analyse d'une predisposition genetique et traitement correspondant
MX2025012588A (es) Tratamiento de la diabetes mellitus
AU2003300224A1 (en) Use of the multifunctional transcription factor yin-yang-1 and variants thereof for treating illnesses, especially type 1 diabetes
Vellenoweth Regulatory pressure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application